Eli Lilly’s decision to withhold 340B drug discounts from hospitals that do not provide pharmacy claims data is escalating the ongoing dispute between pharmaceutical manufacturers and 340B covered entities. The policy, which Lilly says is intended to prevent duplicate discounts and improve oversight, could affect hundreds of hospitals and is expected to trigger additional litigation as providers challenge new conditions being placed on access to 340B pricing. The development comes amid broader pressure on the 340B program, including contract pharmacy restrictions, proposed rebate models, and potential changes to Medicaid eligibility that could impact hospital participation and access to critical 340B savings.
In an article published in Modern Healthcare, Jesse Dresser discussed the operational and legal challenges hospitals face in complying with Lilly’s data-sharing demands, particularly for organizations that lack the infrastructure to provide the requested information. Dresser also noted the broader implications of the policy for the future of the 340B program and provider-manufacturer relations.
“Hospitals are taking into account the precedential impact Eli Lilly’s policy could have, especially if it goes unchallenged.” – Jesse Dresser
